Abstract
Rationale Exhaled breath condensate (EBC) promises a valuable, non-invasive, and easy to obtain clinical sample. However, it is not currently used diagnostically due to poor reproducibility, sample contamination, and sample loss.
Objective We evaluated whether a new, hand-held EBC collector (PBM-HALE™) that separates inertially impacted large droplets (LD) before condensing the fine aerosol (FA) fraction, in distinct self-sealing containers, overcomes current limitations.
Methods Sampling consistency was determined in healthy volunteers by microbial culture, 16S phylogenetics, spectrophotometry, RT-PCR, and HILIC-MS. Capture of aerosolised polystyrene beads, liposomes, virus-like particles, or pseudotyped virus was analysed by nanoparticle tracking analysis, reporter expression assays, and flow cytometry. Acute symptomatic COVID-19 case tidal FA EBC viral load was quantified by RT-qPCR. Exhaled particles were counted by laser light scattering.
Measurements and Main Results Salivary amylase-free FA EBC capture was linear (R2=0.9992; 0.25-30 min) yielding RNA (6.03 μg/mL) containing eukaryotic 18S rRNA (RT-qPCR; p<0.001) but not human GAPDH or beta actin mRNA, and 141 non-volatile metabolites including eukaryotic cell membrane components, and cuscohygrine 3 days after cocaine abuse. Culturable aerobe viability was condensation temperature-dependent. Breath fraction-specific microbiota were stable, identifying Streptococcus enrichment in a mild dry cough case. Nebulized pseudotyped virus infectivity loss <67% depended on condensation temperature, and particle charge-driven aggregation. No SARS-CoV-2 genomes were detected in convalescent or acute COVID-19 patient tidal breath FA EBC.
Conclusions High purity alveolar fraction FA EBC can reproducibly and robustly inform on contamination-free infectious agent emission sources, and be quantitatively assayed for multiple host, microbial, and lifestyle biomarker classes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by the InnovateUK iCURE III project no. 43055, and the Northern Accelerator II project no. 25R18P02557. JAM received funding from the German Research Foundation. Airborne particle size analysis was enabled by the kind loan of equipment by Particles Plus Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All healthy volunteer EBC samples used within this study were obtained with participant informed consent under Northumbria University ethics application no. 43341 approved by the Department of Applied Sciences Subcommittee of University Research Ethics Committee. All COVID-19 patient EBC samples were collected under informed consent under the National and Kapodistrian University of Athens General Hospital Evangelismos ethics application protocol no. 280/24-4-2020 approved by the Scientific Committee of the General Hospital Evangelismos.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This project was supported by the InnovateUK iCURE III project no. 43055, and the Northern Accelerator II project no. 25R18P02557. JAM received funding from the German Research Foundation.Airborne particle size analysis was enabled by the kind loan of equipment by Particles Plus Inc.
We thank Professors Aris Katzourakis, Giorgios Sourvinos, and Manfred Frick regarding study societal impact considerations, organisational aspects of conducting sampling at PAGNI Hospital, and with manuscript review, respectively.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
